Pathophysiology and Therapeutic Advances in Myeloma Bone Disease

Overview

Journal Chronic Dis Transl Med

Publisher Wiley

Date 2022 Nov 24

PMID 36420171

Authors

Fujing Zhang

Junling Zhuang

Affiliations

Soon will be listed here.

Abstract

Bone disease is the most common complication in patients with multiple myeloma (MM), and it may lead to skeletal-related events (SREs) such as bone pain, pathological fractures, and spinal cord compression, which impair a patients' quality of life and survival. The pathogenesis of myeloma bone disease (MBD) involves disruption of bone reconstitution balance including excessive activation of osteoclasts, inhibition of osteoblasts, and participation of osteocytes and bone marrow stromal cells. Various factors, such as the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG), dickkopf-1 (DKK-1), sclerostin, and activin-A, are involved in the development of MBD. Bisphosphonates and the anti-RANKL antibody denosumab are currently the main treatment options for MBD, delaying the onset of SREs. Denosumab is preferred in patients with MM and renal dysfunction. Although effective drugs have been approved, antimyeloma therapy is the most important method for controlling bone disease.

Citing Articles

Enhancing prognosis in multiple myeloma bone disease: insights from a retrospective analysis of surgical interventions.

Shi X, Yao X, Wu Y, Du B, Du X Front Surg. 2025; 11:1433265.

PMID: 39749125 PMC: 11693696. DOI: 10.3389/fsurg.2024.1433265.

Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.

Hanssens H, Meeus F, Gesquiere E, Puttemans J, De Vlaeminck Y, de Veirman K Int J Mol Sci. 2024; 25(11).

PMID: 38891821 PMC: 11171536. DOI: 10.3390/ijms25115634.

Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma.

Zerlotin R, Oranger A, Pignataro P, Dicarlo M, Sanesi L, Suriano C JBMR Plus. 2024; 8(7):ziae066.

PMID: 38855797 PMC: 11162589. DOI: 10.1093/jbmrpl/ziae066.

Efficacy and risk of osteonecrosis of the jaw for pamidronate, zoledronic acid, and denosumab in comparison to alendronate in multiple myeloma patients.

Browne M, Miles B, Mackey J Proc (Bayl Univ Med Cent). 2024; 37(2):227-229.

PMID: 38343457 PMC: 10857533. DOI: 10.1080/08998280.2023.2298667.

The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature Review.

Yamamoto Y, Kondo M, Hotta Y, Tashiro Y, Sanagawa A, Kataoka T Asian Pac J Cancer Prev. 2023; 24(7):2493-2503.

PMID: 37505784 PMC: 10676486. DOI: 10.31557/APJCP.2023.24.7.2493.

References

Winkler D, Sutherland M, Geoghegan J, Yu C, Hayes T, Skonier J . Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22(23):6267-76. PMC: 291840. DOI: 10.1093/emboj/cdg599. View

Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S . Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001; 98(13):3527-33. DOI: 10.1182/blood.v98.13.3527. View

Noll J, Williams S, Tong C, Wang H, Quach J, Purton L . Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2013; 99(1):163-71. PMC: 4007935. DOI: 10.3324/haematol.2013.090977. View

Standal T, Seidel C, Hjertner O, Plesner T, Sanderson R, Waage A . Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002; 100(8):3002-7. DOI: 10.1182/blood-2002-04-1190. View

Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M . Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2004; 126(5):686-9. DOI: 10.1111/j.1365-2141.2004.05092.x. View

Hadjidakis D, Androulakis I . Bone remodeling. Ann N Y Acad Sci. 2007; 1092:385-96. DOI: 10.1196/annals.1365.035. View

Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E . Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008; 26(36):5904-9. DOI: 10.1200/JCO.2008.16.9300. View

Berenson J, Lichtenstein A, Porter L, Dimopoulos M, Bordoni R, George S . Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998; 16(2):593-602. DOI: 10.1200/JCO.1998.16.2.593. View

Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G . The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007; 110(6):2041-8. PMC: 1976367. DOI: 10.1182/blood-2007-04-082495. View

10.

Westendorf J, Kahler R, Schroeder T . Wnt signaling in osteoblasts and bone diseases. Gene. 2004; 341:19-39. DOI: 10.1016/j.gene.2004.06.044. View

11.

Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden A . The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J. 2007; 21(11):2949-60. DOI: 10.1096/fj.07-8080com. View

12.

Hurchla M, Garcia-Gomez A, Hornick M, Ocio E, Li A, Blanco J . The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2012; 27(2):430-40. PMC: 3771507. DOI: 10.1038/leu.2012.183. View

13.

Saad F, Lipton A, Cook R, Chen Y, Smith M, Coleman R . Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110(8):1860-7. DOI: 10.1002/cncr.22991. View

14.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B . The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-94. DOI: 10.1056/NEJMoa030847. View

15.

Roodman G . Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004; 32(2):290-2. DOI: 10.1016/j.bcmd.2004.01.001. View

16.

Abdulkadyrov K, Salogub G, Khuazheva N, Sherman M, Laadem A, Barger R . Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014; 165(6):814-23. PMC: 4312883. DOI: 10.1111/bjh.12835. View

17.

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

18.

Lahtinen R, Laakso M, PALVA I, Virkkunen P, Elomaa I . Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992; 340(8827):1049-52. DOI: 10.1016/0140-6736(92)93075-x. View

19.

Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33. DOI: 10.4065/78.1.21. View

20.

Hu B, Chen Y, Usmani S, Ye S, Qiang W, Papanikolaou X . Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013; 8(9):e74191. PMC: 3774816. DOI: 10.1371/journal.pone.0074191. View